NEOGENOMICS INC
For the period ended Jun 30, 2025. Filed Jul 29, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Jul 29, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
Insider Trading Plans
During our last fiscal quarter, the following officers, as defined in Rule 16a-1(f), adopted a Rule 10b5-1 trading arrangement as defined in Regulation S-K Item 408, as follows:
On June 5, 2025, Alicia Olivo, our Executive Vice President, General Counsel and Business Development, adopted a Rule 10b5-1 trading arrangement providing for the sale from time to time of an aggregate of up to 50,801 shares of our common stock. The trading arrangement is intended to satisfy the affirmative defense in Rule 10b5-1(c). The duration of the trading arrangement is estimated to be from October 4, 2025 to June 30, 2026, or earlier if all transactions under the trading arrangement are completed.
On May 28, 2025, Warren Stone, our President and Chief Operating Officer, adopted a Rule 10b5-1 trading arrangement providing for the sale from time to time of an aggregate of up to 160,908 shares of our common stock. The trading arrangement is intended to satisfy the affirmative defense in Rule 10b5-1(c). The duration of the trading arrangement is estimated to be from November 13, 2025 to April 30, 2026, or earlier if all transactions under the trading arrangement are completed.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.